Provided by Tiger Trade Technology Pte. Ltd.

Insulet

246.41
-11.6650-4.52%
Volume:214.07K
Turnover:53.45M
Market Cap:17.33B
PE:71.40
High:257.19
Open:256.51
Low:245.29
Close:258.07
52wk High:354.88
52wk Low:230.05
Shares:70.35M
Float Shares:70.08M
Volume Ratio:0.69
T/O Rate:0.31%
Dividend:- -
Dividend Rate:- -
EPS(TTM):3.45
EPS(LYR):5.78
ROE:19.68%
ROA:8.74%
PB:12.52
PE(LYR):42.60

Loading ...

Truist Adjusts Price Target on Insulet to $360 From $390, Maintains Buy Rating

MT Newswires Live
·
Yesterday

Truist Financial Sticks to Their Buy Rating for Insulet (PODD)

TIPRANKS
·
Yesterday

Goldman Sachs Sticks to Its Buy Rating for Insulet (PODD)

TIPRANKS
·
Yesterday

Insulet price target lowered to $340 from $380 at Citi

TIPRANKS
·
Yesterday

Insulet price target raised to $286 from $274 at Barclays

TIPRANKS
·
Yesterday

Insulet Corp : Leerink Partners Cuts Target Price to $360 From $386

THOMSON REUTERS
·
Yesterday

Insulet: Strong Q4 Execution and Encouraging 2026 Outlook Offset by Valuation and Competitive Pressures, Justifying Hold Rating

TIPRANKS
·
Yesterday

Insulet: Sustained Growth Runway and Underappreciated Long‑Term Upside Support Buy Rating

TIPRANKS
·
Yesterday

Insulet Price Target Maintained With a $380.00/Share by BTIG

Dow Jones
·
Yesterday

Early notable gainers among liquid option names on February 18th

TIPRANKS
·
Feb 18

Stock Track | Insulet Soars 9.57% Intraday on Strong Q4 Earnings Beat, Robust Omnipod Demand and Upbeat Guidance

Stock Track
·
Feb 18

Insulet Shares up 10% After Q4 Results Beat

THOMSON REUTERS
·
Feb 18

BUZZ-Insulet climbs on better-than-expected quarterly results

Reuters
·
Feb 18

Insulet Shares up 8% Premarket After Q4 Results Beat

THOMSON REUTERS
·
Feb 18

Stock Track | Insulet Soars 5.14% in Pre-market on Strong Q4 Results, Robust Guidance and Share Buyback Plan

Stock Track
·
Feb 18

Insulet beats quarterly estimates on strong demand for wearable insulin pumps

Reuters
·
Feb 18

Insulet Q4 revenue beats on Omnipod strength

Reuters
·
Feb 18

Insulet Publishes Corporate Presentation on Omnipod Growth, AID Leadership, and Product Pipeline

Reuters
·
Feb 18

Insulet Q4 Adj. EPS $1.55 Beats $1.45 Estimate, Sales $783.800M Beat $768.691M Estimate

Benzinga
·
Feb 18

BRIEF-Insulet Q4 Revenue USD 783.8 Million Vs. IBES Estimate USD 768.7 Million

Reuters
·
Feb 18